Related Experiment Video
Updated: May 7, 2026

Two-photon Imaging of Intracellular Ca2+ Handling and Nitric Oxide Production in Endothelial and Smooth Muscle Cells of an Isolated Rat Aorta
Published on: June 10, 2015
The oxygen free radicals control MMP-9 and transcription factors expression in the spontaneously hypertensive rat
Naphatsanan Duansak1, Geert W Schmid-Schönbein
1Department of Bioengineering, Institute of Engineering in Medicine, University of California, San Diego, La Jolla, CA 92093-0412, USA; Division of Physiology, Department of Preclinical Science, Faculty of Medicine, Thammasat University, Pathum Thani 12121, Thailand.
Abstract:
Oxygen free radical and matrix metalloproteinases-9 (MMP-9) play an important pathophysiological role in the development of chronic hypertension. MMP-9 activities are regulated at different levels. We hypothesize that as mediators of the expression of MMP-9 the transcription factors like nuclear factor kappa B (NF-κB), c-fos and retinoic acid receptors-α (RAR-α) with binding sites to the MMP-9 promoter are overexpressed in the spontaneously hypertensive rat (SHR) in a process that is regulated by oxygen free radicals. Transcription factor NF-κB, c-fos and RAR-α expression levels were determined by immunohistochemistry in renal, cardiac and mesentery microcirculation of the SHR and its normotensive control, the Wistar Kyoto (WKY) rat. The animals were treated with a superoxide scavenger (Tempol) for eight weeks. The elevated plasma levels of thiobarbituric acid reactive substances and MMP-9 levels in the SHR were significantly decreased by Tempol treatment (P<0.05). The NF-κB, c-fos and RAR-α expression levels in renal glomerular, heart and mesentery microvessels were enhanced in the SHR and could also be reduced by Tempol compared to untreated animals (P<0.05). The enhanced MMP-9 levels in SHR microvessels co-express with transcription factors. These results suggest that elevated NF-κB, c-fos and RAR-α expressions and MMP-9 activity in the SHR are superoxide-dependent.
Insights
Oxygen free radicals contribute to chronic hypertension by increasing matrix metalloproteinases-9 (MMP-9) and overexpressing transcription factors like nuclear factor kappa B (NF-κB). Treatment with a superoxide scavenger reduced these effects in spontaneously hypertensive rats.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Hypertension Pathophysiology
Background:
- Oxygen free radicals and matrix metalloproteinases-9 (MMP-9) are implicated in chronic hypertension.
- MMP-9 activity is tightly regulated, with transcription factors playing a key role.
Purpose of the Study:
- To investigate the role of superoxide free radicals in regulating MMP-9 expression via transcription factors nuclear factor kappa B (NF-κB), c-fos, and retinoic acid receptors-α (RAR-α) in spontaneously hypertensive rats (SHR).
Main Methods:
- Immunohistochemistry was used to determine the expression levels of NF-κB, c-fos, and RAR-α in the renal, cardiac, and mesenteric microcirculation of SHR and Wistar Kyoto (WKY) rats.
- Animals were treated with the superoxide scavenger Tempol for eight weeks.
- Plasma levels of thiobarbituric acid reactive substances and MMP-9 were measured.
Main Results:
- Tempol treatment significantly reduced elevated plasma thiobarbituric acid reactive substances and MMP-9 levels in SHR.
- Expression of NF-κB, c-fos, and RAR-α was enhanced in the microvessels of SHR and reduced by Tempol treatment.
- Enhanced MMP-9 levels in SHR microvessels were found to co-express with these transcription factors.
Conclusions:
- Elevated NF-κB, c-fos, and RAR-α expression and MMP-9 activity in spontaneously hypertensive rats are dependent on superoxide free radicals.
- Targeting superoxide production may offer a therapeutic strategy for managing hypertension associated with these molecular pathways.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Role of Matrix Metalloproteases in Degradation of ECM
A...
Hypertension and Regulation of Blood Pressure
General Transcription Factors
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
